Things are bad. But at least ‘you can eat’ one of these assets.
Biogen stock rips higher on a promising new drug. Here's what Wall Street is saying.
Threadneedle Street will now start buying bonds to stabilise what it described as 'dysfunctional markets'.
The benchmark S&P 500, which is typically viewed as the best barometer of stock market health, produced its worst first-half return in 52 years. As for the growth-driven Nasdaq Composite, an index largely responsible for pushing the stock market to new highs, it's lost about a third of its value. This puts both the S&P 500 and Nasdaq firmly in a bear market.
These rock-solid income stocks, with yields ranging from 7.8% to 13.8%, are perfectly positioned to make patient investors richer.
The CBOE Volatility Index has skyrocketed 89% so far this year. Morningstar put together a list of stocks with one- and three-year betas of 0.8 or lower. Then it screened for stocks that are undervalued, according to Morningstar analysts' fair value estimates.
Analysts are either optimistic or delusional. But either way, they see a big S&P 500 29% rally coming — and have picked favorite stocks.
Dow Jones futures reversed higher Wednesday, ahead of Fed chief Powell's speech, struggling to avoid a seventh straight decline.
Mizuho analyst Salim Syed says there are enough data on the drug "that likely allows for regulatory approval.
One of the biggest Tesla bears on Wall Street is sticking with his views as rising global recession risks place potential pressure on the EV maker's top and bottom lines.
BENGALURU (Reuters) -The Federal Reserve will hike its key interest rate to a much higher peak than predicted two weeks ago and the risks are skewed towards an even higher terminal rate, according to economists polled by Reuters. That change in expectations came after the Fed raised rates by 75 basis points last week for the third straight meeting and foresaw going higher than it had previously thought to tame inflation, which is running over four times above target. Since then, already battered global stocks went much deeper into bear market territory - a decline of 20% or more - on fears of recession and most currencies weakened further against the multi-decade high dollar.
(Reuters) -Shares in Biogen Inc and Japanese partner Eisai skyrocketed on Wednesday, as a surprise trial success of their experimental Alzheimer's drug was hailed as an unequivocal win by Wall Street analysts. The trial results released on late Tuesday could mark a rare victory in the search for a treatment for the memory-robbing disease after years of clinical failures. Biogen's stock surged 46.6% to $290.99 in premarket trading, putting it on track to add over $13.5 billion in market capitalization.
Apple has cut production of the iPhone 14, after price hikes for its non-US customers and surging inflation around the world led to weaker-than-expected demand.
In this article, we discuss 10 most shorted stocks in the world. If you want to see more stocks on this list, click 5 Most Shorted Stocks in the World. Short squeezes have rapidly gained popularity in the last two years, when retail investors on Reddit gathered to initiate bullish positions in stocks that were […]
As a case in point, Buffett owns more stocks than you'll find listed in Berkshire Hathaway's (NYSE: BRK.A) (NYSE: BRK.B) regulatory filings. You might even say that Buffett has a "secret portfolio." Berkshire's acquisition of General Re years ago brought New England Asset Management (NEAM) into its fold.
Medicare beneficiaries will see their Part B premiums go down for the first time in more than a decade, President Biden said during a press conference on Tuesday. Monthly Part B premiums, which are currently set at $170.10 in 2022, will decline to $164.90 in 2023 – a $5.20 a month savings, or about $64 a year, according to the Centers for Medicare and Medicaid Services. The annual deductible for Part B will be $226, down $7 from $233 in 2022.
Apple is curbing iPhone production. The 10-year yield hit 4%, until the Bank of England stepped in. A Biogen Alzheimer's drug shows promise.
Barring selected periods of relief, the inherent trend of the stock market has been resolutely negative in 2022. For investors searching for ways to boost the portfolio’s performance, there have generally been slim pickings. But if you look on the bright side of a market situation where stocks are continuously pushed further down, what you get are some low and enticing entry points. Roth Capital’s tech and communications expert Scott Searle certainly thinks that with a bit of digging, investors
The 86-year-old investing legend has spoken. Pay attention.
What happened Shares of Novavax (NASDAQ: NVAX) were bouncing back on Tuesday, rising 7.1% as of 12:50 p.m. ET after jumping as much as 14.7% earlier in the day. The gain came after an analyst's downgrade caused the stock to plunge last week.